Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

Video

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Related Videos
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Scott Kopetz, MD, PhD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Scott Kopetz, MD, PhD, FACP
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Related Content
FDA

FDA Approves Noninvasive Stool RNA Screening Test for CRC

May 7th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
Awny Farajallah, MD, of Takeda

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024
Article
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022
Podcast
Heinz-Josef Lenz, MD, University of Southern California Norris Comprehensive Cancer Center

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024
Article
Heinz-Josef Lenz, MD, FACP, of Keck School of Medicine

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024
Article